PRESS ROOM

September 2013

Global Thought-Leaders in Anticoagulation Join XO1 Scientific Advisory Board;

Richard Mason Appointed CEO
Read full Press Release here.

June 2013

XO1 Ltd raises $11million

XO1 Ltd raises $11million from Index Ventures to develop the 'holy grail' of anticoagulant drugs.
Read full Press Release here.

July 2012

Boehringer Ingelheim & Funxional Therapeutics announce acquisition of FX125L

Funxional Therapeutics and Boehringer Ingelheim (BI) today announced the acquisition of the FX125L programme by BI, who will be responsible for further development.
Read full Press Release here.
Read a blog post about the technology here.

January 2012

Epsilon-3 Bio Debuts with Series A

Total Medical Ventures newco Epsilon-3 Bio Ltd has completed a series A financing, led by Index Ventures and Novo Ventures with Imperial Innovations also participating.  The investment will allow the company to evaluate the impact of its apolipoprotein E mimetic drug candidates on a range of inflammatory disease models.